Review analyzes analytical methods for Dapagliflozin and Bisoprolol in combined pharmaceutical formulations, suggesting improvements for quality control.
This review analyse the analytical method associated with the co-administration of Dapagliflozin (an SGLT2 inhibitor) and Bisoprolol (a selective β1-blocker) in managing the heart failure and related metabolic comorbidities. By treating with Bisoprolol counteracts sympathetic overactivation and Dapagliflozin regulate cardiorenal pathways through osmotic diuresis and metabolic optimization, resulting in a complementary reduction in the cardiovascular mortality and hospitalization. This document evaluate analytical techniques developed for their simultaneous estimation in pharmaceutical formulations. We combined established methods covering UV-Vis Spectrophotometry, Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC), High-Performance Thin-Layer Chromatography (HPTLC), and Liquid Chromatography-Mass Spectrometry (LC-MS/MS), highlighting method validation and emerging green analytical chemistry. As a result, this compilation serves as a dual-purpose reference for both the therapeutic purpose and the rigorous quality control work required for this vital cardiorenal and cardiovascular protection combination.
No takes yet. Share an insight, caveat, or question.
S. Arunprasath*1, T. Vetrichelvan Thangarasu2, S. Murugan3 (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: